# Abbott Laboratories

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/abbott-laboratories
Canonical HTML page: https://gethealthbrief.com/entity/abbott-laboratories

## Timeline

- **2026-09-01**: MiniMed scheduled to report fiscal Q1 2027 results — MiniMed Group will report its fiscal Q1 2027 results, the first earnings check after the MiniMed Flex U.S. launch.
- **2026-08-17**: MiniMed announces U.S. commercial shipping of MiniMed Flex with Abbott Instinct — MiniMed Group says its Flex automated insulin delivery system is now shipping in the U.S. integrated with Abbott's Instinct 15-day continuous glucose sensor.

## Recent coverage (3 stories)

### Abbott-MiniMed Flex Diabetes System Ships with 80% Time in Range
2026-08-22 07:04:32 · Sentiment: Positive · Impact: 6/10 · Sources: 2

The Abbott-MiniMed Flex integration is now shipping in the U.S., pairing Abbott's 15-day Instinct sensor with MiniMed's smallest app-controlled insulin pump. Clinicians and health systems gain a real-world data point of 80% Time in Range, while payers will weigh the combined system's value against entrenched CGM and AID competitors.
Full story: https://gethealthbrief.com/story/abbott-minimed-flex-instinct-80-tir

### Abbott lifts 2026 EPS forecast to $5.45-$5.60 on 9% device growth
2026-07-17 03:46:04 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Abbott raises its 2026 profit outlook as medical device sales jump 9% to $5.85B and diabetes care climbs 11%, proving the resilience of advanced cardiac and CGM technologies. The beat and guidance hike signal that hospitals continue to prioritize high-acuity procedures even under volume pressure.
Full story: https://gethealthbrief.com/story/abbott-2026-profit-forecast-device-growth

### Scaling Diabetes Care: The 2026 Outlook for Glucometer Manufacturing
2026-03-23 09:02:25 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

As global diabetes prevalence reaches record highs, the shift toward localized medical device production is driving a surge in glucometer manufacturing plant investments for 2026. This briefing analyzes the cost structures, regulatory hurdles, and technological requirements for establishing high-volume diagnostic production facilities.
Full story: https://gethealthbrief.com/story/glucometer-manufacturing-plant-setup-2026-cost-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.